

## TABLE OF CONTENTS

<b>Contents</b>	<b>Page No.</b>
<b>Abstract</b>	<b>i-vii</b>
<b>Declaration</b>	
<b>Certificate</b>	
<b>Acknowledgments</b>	<b>viii-ix</b>
<b>Table of Contents</b>	<b>x-xvii</b>
<b>List of Tables</b>	<b>xviii-xx</b>
<b>List of Figures</b>	<b>xxi-xxvii</b>
<b>Abbreviations</b>	<b>xxviii-xxx</b>

### **CHAPTER-I**

<b>INTRODUCTION</b>	<b>1-35</b>
1.1 Introduction	2
1.2 Progression of blood clotting or thrombus formation	2-3
1.3 Thrombolysis and fibrinolysis	3-4
1.4 Molecular mechanism of fibrin formation	4-6
1.5 Classification of thrombolytic agents	6-7
1.5.1 Direct-acting fibrinolytic enzymes	7
1.5.1.1 Nattokinase	7-9
1.5.2 Indirect-acting fibrinolytic enzymes	9
1.5.2.1 Streptokinase	9-10
1.5.2.2 Staphylokinase	10-11
1.5.2.3 Urokinase	11-12
1.5.2.4 Tissue plasminogen activator	12-13
1.5.3 Anticoagulant	13-14
1.5.3.1 Heparin	14-15
1.5.3.2 Vitamin K antagonist	15-16
1.5.3.3 Novel oral anticoagulants	16-18
1.5.4 Antiplatelet drugs	19-20
1.5.4.1 Aspirin	20
1.5.4.2 ADP receptor inhibitors: Ticlopidine and Clopidogrel	20-21
1.5.4.3 GPIIb/IIIa inhibitors	21-23

1.6 Limitations of thrombolytic drugs	23-25
1.7 Aims and objectives of the study	25-26
Bibliography	26-35

<b>Contents</b>	<b>TABLE OF CONTENTS</b>	<b>Page no.</b>
-----------------	--------------------------	-----------------

## **CHAPTER-II**

<b>REVIEW OF LITERATURE</b>	<b>36-74</b>
2.1 Overview of fibrinolytic enzyme	37
2.2 Non-food sources of fibrinolytic enzymes	38-40
2.3 Fibrinolytic enzymes from food sources	40-43
2.4 Production of fibrinolytic enzyme by recombinant cloning and expression method	43-50
2.5 Physiochemical properties of fibrinolytic enzymes produced by <i>Bacillus</i> spp.	51-54
2.6 Fibrinolytic activity assessment	55-56
2.7 Pharmacological, thrombolytic, and toxicological assessment of fibrinolytic enzymes derived from <i>Bacillus</i> spp.	56-60
2.8 Structural-functional characteristics	60-61
Bibliography	62-74

<b>Contents</b>	<b>TABLE OF CONTENTS</b>	<b>Page no.</b>
-----------------	--------------------------	-----------------

## **CHAPTER-III**

<b>MATERIALS AND METHODS</b>	<b>75-106</b>
3.1 Materials	76-77
3.1.1 Chemicals	76
3.1.1.1 Analytical grade	76
3.1.1.2 Microbiological grade culture media/chemicals	76
3.1.1.3 Molecular cloning and expression	76
3.1.1.4 Cell culture reagents	77

3.1.1.5 Serum profiling	77
3.2 Methods	77-
3.2.1 Computational ( <i>in silico</i> ) analysis to study bacterial fibrinolytic proteases' structure-function relationship	77-79
3.2.1.1 Sequence retrieval and alignment	77
3.2.1.2 Determination of physiochemical characteristics of the proteins	77
3.2.1.3 Structure analyses of fibrinolytic proteases	78
3.2.1.4 Functional analysis	78-79
3.2.1.5 Validation of the <i>in-silico</i> data analysis	79
3.2.2 Isolation and characterization of fibrinolytic enzyme producing bacteria from few fermented food/starter culture samples of Northeastern, India	79-90
3.2.2.1 Collection of fermented food/starter culture samples	79
3.2.2.2 Screening of protease-producing bacteria	79
3.2.2.3 Fibrinolytic protease production	79-80
3.2.2.3.1 Protein estimation	80-81
3.2.2.3.2 Measurement of zone of hydrolysis on fibrin agar plate	81
3.2.2.3.3 Fibrinolytic assay	81
3.2.2.3.3.1 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis	82-83
3.2.2.4 Pure culture of fibrinolytic protease-secreting bacterial isolates	83
3.2.2.5 Identification of bacterial strain	83
3.2.2.5.1 Morphological traits	84
3.2.2.5.1.1 Gram's staining	84
3.2.2.5.2 Biochemical test	84
3.2.2.5.2.1 Carbohydrate fermentation test	84
3.2.2.5.2.2 Triple sugar iron agar test	85
3.2.2.5.2.3 Catalase test	85
3.2.2.5.2.4 Citrate utilization test	85
3.2.2.5.2.5 Indole production test	86
3.2.2.5.2.6 Oxidase test	86
3.2.2.5.2.7 Urease test	86
3.2.2.5.2.8 Methyl red-Voges-Proskauer test	87

3.2.2.5.3 16s rDNA sequencing	87
3.2.2.5.3.1 Genomic DNA isolation	87
3.2.2.5.3.2 Agarose gel electrophoresis	87-88
3.2.2.5.3.3 PCR amplification of 16s rDNA gene	88-89
3.2.2.5.3.5 Gel extraction of PCR product	89
3.2.2.5.3.6 Phylogenetic analysis	89
3.2.2.6 PCR amplification of fibrinolytic protease encoding gene	89-90
3.2.2.7 Computation analysis of amplified fibrinolytic encoding gene sequence	90
3.2.3 Cloning, expression, purification, and characterization of a recombinant bacterial fibrinolytic serine protease enzyme	91-106
3.2.3.1 Cloning of protease gene	91
3.2.3.1.1 Codon optimization and synthesis of protease gene	91
3.2.3.1.2 Preparation of BL21 competent cells	91-92
3.2.3.1.3 Transformation of synthetic plasmid into BL21 competent cells	92
3.2.3.1.4 Screening of transformed recombinant colony	92-93
3.2.3.2 Expression of recombinant protease	93
3.2.3.2.1 Renaturation by dialysis	93-94
3.2.3.2.2 Renaturation by direct mixing with refolding solution	94
3.2.3.2.3 Renaturation using urea	94-95
3.2.3.3 Purification of recombinant protease by Ni-NTA affinity chromatography	95-96
3.2.3.4 Biochemical characterization of recombinant fibrinolytic protease	96
3.2.3.4.1. Protein estimation	96
3.2.3.4.2 Determination of molecular weight and purity of purified fibrinolytic protease by SDS-PAGE analysis	96
3.2.3.4.3 Fibrinolytic assay	96
3.2.3.4.3.1 Colorimetric assay	96
3.2.3.4.3.2 SDS-PAGE analysis	97
3.2.3.4.4 Effect of metal ions on protease activity by colourimetric method	97
3.2.3.4.5 Determination of interaction between the recombinant protease and thrombin by spectrofluorometric analysis	97-98

3.2.3.5 Pharmacological characterization of recombinant fibrinolytic protease	98
3.2.3.5.1 Hemolytic assay	98
3.2.3.5.2 Anticoagulant assay	98
3.2.3.5.3 Determination of activated partial thromboplastin time	99
3.2.3.5.4 Determination of prothrombin time	99
3.2.3.5.5 <i>In vitro</i> thrombolytic assay	99-100
3.2.3.5.6 Effect on inhibition of fibrinogen clotting time of thrombin	100
3.2.3.5.7 Platelet modulating activity of recombinant protease	100
3.2.3.6 Cell cytotoxicity assay of recombinant fibrinolytic protease	100-101
3.2.3.7 <i>In vivo</i> toxicity assessment	101
3.2.3.7.1 <i>In vivo</i> anticoagulant potency of recombinant protease in swiss albino mice	101-102
3.2.3.7.2 <i>In vivo</i> toxicity assessment in rat model	102-103
3.2.3.7.3 Histopathological study	103
3.2.4 Statistical analysis	103
Bibliography	104-106

---

Contents	TABLE OF CONTENTS	Page no.
----------	-------------------	----------

---

#### CHAPTER-IV

<b>Computational (<i>in silico</i>) analysis to study bacterial fibrinolytic proteases' structure-function relationship</b>	107-179
4.1. Brief introduction	108-110
4.2 Results	110
4.2.1 Sequence retrieval and alignment	110-115
4.2.2 <i>In silico</i> prediction of physiochemical properties of the fibrinolytic enzymes	115-125
4.2.3 Structural analysis	125
4.2.3.1 Primary sequence analysis	125-129
4.2.3.2 Secondary structure analysis	129-142
4.2.3.3 Tertiary structure analysis	143-150

---

4.2.4 Functional analysis of fibrinolytic enzymes	151-160
4.2.5 Validation of <i>in-silico</i> data	160-162
4.3 Discussion	162-168
Bibliography	168-179

---

Contents	TABLE OF CONTENTS	Page no.
----------	-------------------	----------

---

### CHAPTER-V

<b>Isolation and characterization of fibrinolytic enzyme producing bacteria from few fermented food/starter culture samples of Northeastern, India</b>	<b>180-198</b>
5.1 Brief introduction	181-182
5.2 Results	182
5.2.1 Screening of fibrinolytic enzyme-producing bacteria	182-183
5.2.2 Fibrinolytic protease production	183
5.2.2.1 Zone of hydrolysis	183-184
5.2.2.2 Fibrinolytic assay	184-185
5.2.3 Pure culture of fibrinolytic-producing bacterial isolates	185-186
5.2.4 Identification of bacterial strains	186
5.2.4.1 Morphological and biochemical identification	186-187
5.2.4.2 Genomic DNA isolation and PCR amplification of 16s rDNA gene	187
5.2.4.3 Phylogenetic tree analysis of bacterial isolates based on 16s rDNA sequencing	188-190
5.2.5 PCR amplification of protease gene	191
5.2.6 Computational analysis of amplified fibrinolytic encoding gene sequence	191-192
5.3 Discussion	192-194
Bibliography	195-198

---

Contents	TABLE OF CONTENTS	Page no.
<b>CHAPTER-VI</b>		
<b>Cloning, expression, purification and characterization of a recombinant bacterial fibrinolytic serine protease enzyme</b>		<b>199-225</b>
6.1 Brief introduction		200-201
6.2 Results		201
6.2.1 Codon optimization and gene synthesis		201-202
6.2.2 Transformation of synthetic plasmid into BL21 competent cells and sequence analysis		202-205
6.2.2 Expression and purification of recombinant protease gene		205-206
6.2.3 The purified protease exhibited fibrinolytic activity but not fibrinogenolytic activity		207-209
6.2.4 Inhibitory activity of recombinant protease		209
6.2.5 Recombinant protease shows interaction with thrombin and inhibits the catalytic activity of thrombin		209-210
6.2.6 Dose-dependent anticoagulant activity of purified recombinant protease		211
6.2.7 Purified recombinant protease exhibited <i>in vitro</i> thrombolytic activity		212
6.2.8 Recombinant protease is deprived of hemolytic activity and cytotoxicity against NRK-52 <sup>E</sup> cells		212-213
6.2.9 Purified recombinant protease showed antiplatelet activity		213
6.2.10 <i>In vivo</i> anticoagulant and toxicity assay of recombinant protease		213-215
6.2.11 Effect on serum biochemical parameters of recombinant protease-treated rat		215-216
6.2.12 Histopathological study of tissues obtained from recombinant protease-treated and control group of rat		216-217
6.3 Discussion		217-221
Bibliography		221-225

<b>Contents</b>	<b>TABLE OF CONTENTS</b>	<b>Page no.</b>
<b>CHAPTER-VII</b>		
<b>CONCLUSIONS AND FUTURE PERSPECTIVES</b>		<b>226-228</b>
7.1	Conclusions	227-228
7.2	Future perspectives	228
<b>Publications, and Conferences/Seminars</b>		<b>229</b>
<b>Appendix</b>		<b>230-231</b>